

## CORRECTION

# Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

Benny Sørensen<sup>1\*</sup>, Donat R Spahn<sup>2</sup>, Petra Innerhofer<sup>3</sup>, Michael Spannagl<sup>4</sup> and Rolf Rossaint<sup>5</sup>

See related review by Sørensen *et al.*, <http://ccforum.com/content/15/1/201>

### Correction

After publication of our article [1] we noted that in Table 1 for Prothrombinex-VF 'Antithrombin and heparin added' should have been included under the 'Additional information' column. A copy of the table with the correct information can be found overleaf.

### Author details

<sup>1</sup>Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy's and St Thomas' Hospital & NHS Trust Foundation, King's College London School of Medicine, 1st Floor, North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK. <sup>2</sup>Institute of Anesthesiology, University Hospital Zurich, CH-8091 Zurich, Switzerland. <sup>3</sup>Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. <sup>4</sup>Working Group on Perioperative Hemostasis, Department of Anaesthesiology, University Hospital of Munich, Nussbaumstrasse 20, 80336 Munich, Germany. <sup>5</sup>Department of Anaesthesiology, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.

Published: 18 March 2011

### Reference

1. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: **Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity.** *Crit Care* 2011, **15**:201.

doi:10.1186/cc10094

**Cite this article as:** Sørensen B, *et al.*: Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. *Critical Care* 2011, **15**:409.

\*Correspondence: [benny.sorensen@kcl.ac.uk](mailto:benny.sorensen@kcl.ac.uk)

<sup>1</sup>Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy's and St Thomas' Hospital & NHS Trust Foundation, King's College London School of Medicine, 1st Floor, North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK  
Full list of author information is available at the end of the article

**Table 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates**

Brand name	Manufacturer	International units relative to factor IX				Viral inactivation	Additional information
		Factor II	Factor VII	Factor IX	Factor X		
Bebulin VH	Baxter BioScience, Austria	120	(13)	100	100	Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar	Heparin added
Beriplex P/N	CSL Behring, Germany	128	68	100	152	Pasteurisation at 60°C for 10 hours, and nanofiltration	Protein C; antithrombin, heparin and albumin added
Cofact	Sanquin, the Netherlands	56-140	28-80	100	56-140	Solvent/detergent and 15 nm nanofiltration	Antithrombin added
KASKADIL	LFB, France	148	40	100	160	Solvent/detergent	Heparin added
Octaplex	Octapharma, Austria and France	44-152	36-96	100	50	Solvent/detergent and nanofiltration	Heparin added; low activated factor VII content
Profilnine SD	Grifols, USA	148	(11)	100	64	Solvent/detergent	–
Prothrombinex VF	CSL Bioplasma, Australia	100	(–)	100	100	Dry heat, 80°C for 72 hours and nanofiltration	Antithrombin and heparin added
Prothromplex T	Baxter BioScience, Austria	100	85	100	100	Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar	Antithrombin and heparin added
UMAN Complex D.I.	Kedrion, Italy	100	(–)	100	80	Solvent/detergent and dry heat, 100°C for 30 minutes	Antithrombin and heparin added

Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.